
|Articles|March 31, 2008
FDA requires REMS plan for 25 drugs, biologics
FDA issues a notice requiring the manufacturers of 25 high-risk drugs and biologics to submit a REMS plan.
Advertisement
In a notice published in the March 27
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
REM-Dominant Sleep Apnea Is Significantly More Prominent Following COVID-19
2
Trump Executive Order Set to Reclassify Marijuana, Improve CBD Access
3
Most Favored Nation: Global Benchmarking to Reimagine US Drug Distribution
4
From Policy to Practice: Elevating Pharmacy’s Role in Quality and Patient Safety
5






















































































































